1. Pathologist at the doorstep of cancer “I know your weaknesses and strength”: an interview with Jean Claude Reubi

   • Vikas Prasad

   Interview 04 February 2020 Pages: 741 - 743

   

2. ¹⁶⁶Ho microsphere scout dose for more accurate radioembolization treatment planning

   • C Chiesa
   • M Maccauro

   Editorial 24 December 2019 Pages: 744 - 747

3. Ethical principles for the application of artificial intelligence (AI) in nuclear medicine

   • Geoff Currie
   • K Elizabeth Hawk
   • Eric M. Rohren

   Editorial 11 January 2020 Pages: 748 - 752

   

4. The importance of differentiating between qualitative, semi-quantitative, and quantitative imaging—close only counts in horseshoes

   • Richard M. Fleming
   • Matthew R. Fleming
   • Tapan K. Chaudhuri

   Editorial 17 January 2020 Pages: 753 - 755

   

5. Availability of both [¹⁷⁷Lu]Lu-DOTA-TATE and [⁹⁰Y]Y-DOTATATE as PRRT agents for neuroendocrine tumors: can we evolve a rational sequential duo-PRRT protocol for large volume resistant tumors?

   • Sandip Basu
   • Rahul V. Parghane
   • Sharmila Banerjee

   Letter to the Editor 18 October 2019 Pages: 756 - 758

   

6. Staging FDG PET-CT changes management in patients with gastric adenocarcinoma who are eligible for radical treatment

   • Karen D. Bosch
   • Sugama Chicklore
   • Cara R. Baker

   Original Article Open access 03 August 2019 Pages: 759 - 767

   

7. ¹⁸F-FDG PET-MR enterography in predicting histological active disease using the Nancy index in ulcerative colitis: a randomized controlled trial

   • Yan Li
   • Benedikt Schaarschmidt
   • Jost Langhorst

   Original Article 24 October 2019 Pages: 768 - 777

   

8. Incidental ¹⁸F-FDG uptake in the colon: value of contrast-enhanced CT correlation with colonoscopic findings

   • Julian Kirchner
   • Benedikt M. Schaarschmidt
   • Philipp Heusch

   Original Article 07 November 2019 Pages: 778 - 786

   

9. Hypoxia-induced modulation of glucose transporter expression impacts ¹⁸F-fluorodeoxyglucose PET-CT imaging in hepatocellular carcinoma

   • Hongping Xia
   • Jianxiang Chen
   • Kam M. Hui

   Original Article 12 December 2019 Pages: 787 - 797

   

10. The superior predictive value of ¹⁶⁶Ho-scout compared with ^99mTc-macroaggregated albumin prior to ¹⁶⁶Ho-microspheres radioembolization in patients with liver metastases

    • Maarten L. J. Smits
    • Mathijs G. Dassen
    • Marnix G. E. H. Lam

    Original Article Open access 09 August 2019 Pages: 798 - 806

    

11. Safety and efficacy of radioembolization with glass microspheres in hepatocellular carcinoma patients with elevated lung shunt fraction: analysis of a 103-patient cohort

    • Arighno Das
    • Ahsun Riaz
    • Riad Salem

    Original Article 10 September 2019 Pages: 807 - 815

    

12. The number of microspheres in Y90 radioembolization directly affects normal tissue radiation exposure

    • Alexander S. Pasciak
    • Godwin Abiola
    • Clifford R. Weiss

    Original Article 18 November 2019 Pages: 816 - 827

    

13. Comparative dosimetry between ^99mTc-MAA SPECT/CT and ⁹⁰Y PET/CT in primary and metastatic liver tumors

    • Alexandre Jadoul
    • Claire Bernard
    • Roland Hustinx

    Original Article 06 August 2019 Pages: 828 - 837

    

14. Quantifying the effects of absorbed dose from radioembolisation on healthy liver function with [^99mTc]TcMebrofenin

    • Kathy P Willowson
    • Geoffrey P Schembri
    • Dale L Bailey

    Original Article 20 January 2020 Pages: 838 - 848

    

15. [⁸⁹Zr]Zr-cetuximab PET/CT as biomarker for cetuximab monotherapy in patients with RAS wild-type advanced colorectal cancer

    • E. J. van Helden
    • S. G. Elias
    • C. W. Menke-van der Houven van Oordt

    Original Article Open access 09 November 2019 Pages: 849 - 859

    

16. Evaluation of [⁶⁸Ga]Ga-DATA-TOC for imaging of neuroendocrine tumours: comparison with [⁶⁸Ga]Ga-DOTA-NOC PET/CT

    • Divya Yadav
    • Sanjana Ballal
    • Chandrasekhar Bal

    Original Article 22 November 2019 Pages: 860 - 869

    

17. Biodistribution and first clinical results of ¹⁸F-SiFAlin-TATE PET: a novel ¹⁸F-labeled somatostatin analog for imaging of neuroendocrine tumors

    • Harun Ilhan
    • S. Lindner
    • P. Bartenstein

    Original Article 06 September 2019 Pages: 870 - 880

    

18. Prognostic Significance of Somatostatin Receptor Heterogeneity in Progressive Neuroendocrine Tumor Treated with Lu-177 DOTATOC or Lu-177 DOTATATE

    • Josephine Graf
    • Ulrich-Frank Pape
    • Vikas Prasad

    Original Article 14 August 2019 Pages: 881 - 894

    

19. PRRT neuroendocrine tumor response monitored using circulating transcript analysis: the NETest

    • Lisa Bodei
    • Mark S. Kidd
    • Irvin M. Modlin

    Original Article 14 December 2019 Pages: 895 - 906

    

20. Combination treatments to enhance peptide receptor radionuclide therapy of neuroendocrine tumours

    • Samuel Adant
    • Girish M. Shah
    • Jean-Mathieu Beauregard

    Review Article 06 September 2019 Pages: 907 - 921

    

21. Tandem peptide receptor radionuclide therapy using ⁹⁰Y/¹⁷⁷Lu-DOTATATE for neuroendocrine tumors efficacy and side-effects - polish multicenter experience

    • Jolanta Kunikowska
    • Anna Zemczak
    • Leszek Królicki

    Original Article Open access 24 January 2020 Pages: 922 - 933

    

22. Broadening horizons with ²²⁵Ac-DOTATATE targeted alpha therapy for gastroenteropancreatic neuroendocrine tumour patients stable or refractory to ¹⁷⁷Lu-DOTATATE PRRT: first clinical experience on the efficacy and safety

    • Sanjana Ballal
    • Madhav Prasad Yadav
    • Madhavi Tripathi

    Original Article 10 November 2019 Pages: 934 - 946

    

23. Dose escalation of an Evans blue–modified radiolabeled somatostatin analog ¹⁷⁷Lu-DOTA-EB-TATE in the treatment of metastatic neuroendocrine tumors

    • Qingxing Liu
    • Yuejuan Cheng
    • Xiaoyuan Chen

    Original Article 12 December 2019 Pages: 947 - 957

    

24. Preclinical evaluation of [¹⁸F]FB-A20FMDV2 as a selective marker for measuring α_Vβ₆ integrin occupancy using positron emission tomography in rodent lung

    • Mayca Onega
    • Christine A. Parker
    • Jan Passchier

    Original Article Open access 03 January 2020 Pages: 958 - 966

    

25. Clinical quantification of the integrin αvβ6 by [¹⁸F]FB-A20FMDV2 positron emission tomography in healthy and fibrotic human lung (PETAL Study)

    • Pauline T. Lukey
    • Christopher Coello
    • Richard P. Marshall

    Original Article Open access 09 December 2019 Pages: 967 - 979

    

26. The radiosensitizer Onalespib increases complete remission in ¹⁷⁷Lu-DOTATATE-treated mice bearing neuroendocrine tumor xenografts

    • Sara Lundsten
    • Diana Spiegelberg
    • Marika Nestor

    Original Article Open access 07 January 2020 Pages: 980 - 990

    

27. Noninvasive PET tracking of post-transplant gut microbiota in living mice

    • Yanpu Wang
    • Chenran Zhang
    • Zhaofei Liu

    Original Article 02 January 2020 Pages: 991 - 1002

    

28. TOPKi-NBD: a fluorescent small molecule for tumor imaging

    • Giacomo Pirovano
    • Sheryl Roberts
    • Thomas Reiner

    Original Article 16 November 2019 Pages: 1003 - 1010

    

29. A case of abdominal wall percutaneous endoscopic gastrostomy site metastatic disease from primary oropharyngeal squamous cell carcinoma

    • S. L. Ayesa
    • S. F. Hain

    Image of the Month 27 January 2020 Pages: 1011 - 1012

    

30. Granulomatous hepatitis masquerading as metastases on FDG PET/CT

    • Sayak Choudhury
    • Archi Agrawal
    • Venkatesh Rangarajan

    Image of the Month 22 October 2019 Pages: 1013 - 1014

    

31. An aggressive functioning pituitary adenoma treated with peptide receptor radionuclide therapy

    • Majid Assadi
    • Reza Nemati
    • Hojjat Ahmadzadehfar

    Image of the Month 18 November 2019 Pages: 1015 - 1016

    

32. Correction to: A multiparametric analysis based on DCE-MRI to improve the accuracy of parotid tumor discrimination

    • Zhifeng Xu
    • Shaoyan Zheng
    • Mingyong Gao

    Correction 04 February 2020 Pages: 1017 - 1017